ZLNA Zelluna ASA
Zelluna ASA, a clinical-stage biotechnology company, engages in the development of T-cell receptor guided natural killer cell therapies in Norway. It develops ZI-MA4-1 which is in Phase I clinical trial for the treatment of non-small cell lung cancer, ovarian, and head and neck synovial sarcoma; ZI-KL1-1 which is in preclinical trial for the treatment of breast, gastric, lung, pancreatic, and cervix cancers; and ZI-PR-1 which is in discovery stage for the treatment of solid tumors. The company was incorporated in 2016 and is headquartered in Oslo, Norway.…
Industry Peers
BiotechnologyKey Statistics
About Zelluna (OSL: ZLNA)
›
Zelluna (OSL: ZLNA) is listed on Oslo Børs, where its shares trade in NOK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 15 employees.
The shares were at 14.70 NOK on 20 November 2026, up 65.2% over 52 weeks. Its 52-week range is 8.204 NOK to 35.80 NOK: the price is 58.9% below the high and 79.2% above the low.
Its market capitalisation is 438.95M NOK.
Zelluna reports return on equity of -46.8%.
It holds more cash than debt, a net cash position of 59.57M NOK. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 11 February 2027.